Journal September 16, 2026 5 min read

Oxytocin acetate: sourcing, documentation and price

A research-supply overview of oxytocin acetate: formal identifiers, receptor pathway, study findings across models, and documentation considerations for laboratory procurement.

peptides-pro Editorial

What oxytocin acetate is

Oxytocin acetate is the acetate salt of oxytocin, a cyclic nonapeptide hormone. Synonyms include oxytocin diacetate and α-hypophamine acetate. It belongs to the neurohypophyseal hormone class. The evidence block for this page does not provide sequence, molecular formula, or molecular weight, so those identifiers are not stated here. The work described below centres on the oxytocin receptor, a G-protein-coupled receptor that also binds vasopressin with lower affinity, and on the vasopressin/oxytocin neuroendocrine axis.

Oxytocin acetate is supplied for laboratory research use only. It is not a therapeutic product and no human dose is given on this page.

Research Studies

Oxytocin acetate and uterine involution in dairy cows

A study in dairy cows compared three substances with ecbolic activity — oxytocin, prostaglandin F2α, and scopolamine — for their effect on uterine involution and resumption of ovarian activity [3]. Eighty bovine were randomly divided into four groups of 20. Group C received 5 mL/head of saline within 24 h of calving; Group PG received 150 µg/head of d-cloprostenol; Group OX received 50 IU/head of oxytocin acetate; Group S received 40 mg of scopolamine butylbromide. Blood samples were collected to evaluate hydroxyproline. This is an animal-only finding; no equivalent controlled involution data in humans are provided in the evidence block.

Oxytocin and endogenous release in pediatric pituitary disease

An open-label interventional pilot trial is recruiting 10 youth with arginine-vasopressin deficiency (AVP-D) and 10 pediatric patients with pituitary disease matched for age, sex, and BMI from Pediatric Endocrinology and Neuroendocrinology at Massachusetts General Hospital and the community [1]. The study tests the hypothesis that oral estrogen/progestin will stimulate endogenous oxytocin release in control subjects. Eligible participants receive two tablets in a single administration containing a total of 1 mg norethindrone acetate and 70 µg ethinyl estradiol. Blood and saliva are sampled at baseline and approximately 24 hours after study drug administration, alongside neuropsychological assessment of anxiety, mood, and emotion regulation. This is a registered protocol; results are not reported in the evidence block.

Oxytocin and estrogen-progestin response in adults with pituitary disease

A separate open-label pilot study characterizes oxytocin response to a single oral dose of estrogen-progestin in patients with arginine-vasopressin deficiency compared with healthy controls [2]. The stated hypotheses are that salivary and blood oxytocin response to estrogen-progestin will be lower in AVP-D than in healthy controls, and that lower salivary and blood oxytocin levels will be associated with more severe symptoms of anxiety, depression, and social-emotional difficulties as well as lower quality of life. This is a registered protocol; results are not reported in the evidence block.

Oxytocin receptor antagonism and preterm labour

A randomized, double-blind, double-dummy study compared retosiban with atosiban for women in spontaneous preterm labour [7]. The primary objective was to demonstrate superiority of retosiban in prolonging pregnancy. Atosiban is described in the protocol as a mixed oxytocin/vasopressin antagonist indicated for short-term use to delay imminent preterm birth in women between 24^0/7 and 33^6/7 weeks' gestation. This study concerns oxytocin receptor antagonism rather than oxytocin acetate administration, and the evidence block does not report its results.

Oxytocin agonist and rTMS in a mouse model of postpartum depression

A study in mice examined the combination of repetitive transcranial magnetic stimulation (rTMS) and an oxytocin agonist and reported attenuation of depression-like behaviour after postpartum depression [8]. The paper notes that DSM-5 categorizes postpartum depression as a subtype of major depressive disorder with peripartum onset, generally arising within the initial trimester following delivery, and characterizes it as an acute psychiatric condition. This is an animal-only finding; it does not establish an effect in humans.

Oxytocin and cardiac output during cesarean delivery

A registered study plans to measure cardiac output in healthy parturients undergoing cesarean delivery under spinal anesthesia [4]. The evidence block does not state that oxytocin acetate is administered as part of this protocol, nor does it report results. The relevance to oxytocin research is contextual rather than direct.

Oxytocin-pathway compounds and fluid assessment in preeclampsia

Two registered studies concern parturients with preeclampsia undergoing cesarean section. One evaluates ultrasonography for fluid assessment [5]; the other compares combined colloids and crystalloids with crystalloids alone in women with preeclampsia undergoing elective cesarean delivery under spinal anesthesia [6]. The evidence block for [5] notes that preeclampsia is a multifocal syndrome reported in 2–8% of pregnancies, diagnosed in the second half of pregnancy by two separate measurements of systolic blood pressure ≥140 mmHg and/or diastolic blood pressure ≥90 mmHg in the same arm and proteinuria >300 mg in 24 h urine collection, and that the risk for serious complications such as pulmonary edema, cerebrovascular accidents, coagulopathy, and hemorrhage is 10- to 30-fold higher among parturients with severe preeclampsia. Neither study is reported in the evidence block as administering oxytocin acetate, and neither reports results.

Comparison of study models

Study	Model / population	Compound or intervention	Reported outcome
[3]	Dairy cows, 80 animals, 4 groups	Oxytocin acetate 50 IU/head vs d-cloprostenol, scopolamine, saline	Uterine involution and ovarian activity; blood hydroxyproline measured
[1]	Pediatric patients with AVP-D and pituitary disease, n=20 planned	Oral norethindrone acetate 1 mg + ethinyl estradiol 70 µg	Protocol only; oxytocin release hypothesis
[2]	Adults with AVP-D vs healthy controls	Single oral estrogen-progestin dose	Protocol only; oxytocin response and psychopathology associations
[7]	Women in spontaneous preterm labour	Retosiban vs atosiban	Protocol only; time to delivery
[8]	Mice, postpartum depression model	rTMS + oxytocin agonist	Depression-like behaviour attenuated (animal-only)

Sourcing and documentation

Oxytocin acetate for laboratory use is typically supplied with a certificate of analysis stating identity, purity, and counter-ion content. Because the evidence block does not provide sequence, formula, or molecular weight, purchasers should confirm those identifiers against the supplier's own documentation rather than relying on this page. The studies cited above span veterinary, pediatric, adult, and rodent models; none of them establishes a human dose or a clinical outcome for oxytocin acetate as a research chemical.

If you are reading this for personal health reasons

This material is sold for laboratory research only. We do not provide dosing or medical guidance. Anyone considering a compound for themselves should speak to a licensed clinician.